Current Edition

announces

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Investigator-led study has commenced dosing Immunotherapy candidate CV301 is being assessed in combination with checkpoint inhibitors in multiple solid tumors Bavarian Nordic A/S (OMX: BAVA, …

Continue Reading →
clinical

OncBioMune Signs Work Order for Phase 2 Clinical Trial of ProscaVax for Early Stage Prostate Cancer

Opthea Recruits 176th Patient and On-Track to Report Primary Data Analysis Early 2020 OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company …

Continue Reading →
clinical

CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD

Patient enrollment proceeding under amended protocol CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company developing new antibody therapies for combating human immunodeficiency virus (HIV) infection and immunologic …

Continue Reading →
Europe

Madrigal scores in mid-stage NASH study

Madrigal Pharmaceuticals on Thursday reported highly anticipated results for its Phase 2 non-alcoholic steatohepatitis (NASH) drug MGL-3196, unveiling positive data after 36 weeks. The study …

Continue Reading →
Europe

Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine

Pediatric Study Demonstrated Improvements in Rickets Severity, Growth, Pain and Physical Activity in Children with Debilitating, Lifelong Hereditary Disease Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), Kyowa …

Continue Reading →
MABp1

XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis

First Patient Begins Therapy with MABp1 for Treatment of Atopic Dermatitis XBiotech Inc. (NASDAQ:XBIT) announced today that the first patient has been enrolled in its …

Continue Reading →
data

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in …

Continue Reading →